Verified Nov 2026
Other
·

Rockville, Maryland
·
Since 2005
Supernus Pharmaceuticals is a biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, with 500-1,000 employees and estimated revenue of $500M-1B. It develops and commercializes treatments for central nervous system disorders including opioid use disorder, ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine. In November 2026, Supernus completed a merger with Indivior to create a diversified CNS biopharmaceutical company.
Supernus Pharmaceuticals, Inc. at a glance
Revenue
$500M-1B
Est. band
Employees
500-1,000
Founded
2005
Headquarters
Rockville, Maryland
Industries
Automotive
Electric Vehicles
Medical
Overview
Supernus Pharmaceuticals is a biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, with 500-1,000 employees and estimated revenue of $500M-1B. It develops and commercializes treatments for central nervous system disorders including opioid use disorder, ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine. In November 2026, Supernus completed a merger with Indivior to create a diversified CNS biopharmaceutical company.
At a glance
Attribute | Detail |
|---|---|
Founded | 2005 |
Headquarters | Rockville, Maryland |
Employees | 500-1,000 |
Revenue | $500M-1B (estimated) |
What Supernus Pharmaceuticals, Inc. makes
The company's portfolio includes approved treatments for multiple CNS conditions and employs proprietary platforms such as an apomorphine infusion device and extended-release formulations.
Latest developments
2026-11-02 — Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader - Supernus Pharmaceuticals (supernus.com)
2026-10-29 — Supernus Announces Third Quarter 2026 Financial Results - Supernus Pharmaceuticals (supernus.com)
2026-08-03 — Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale - Supernus Pharmaceuticals (supernus.com)
2026-06-17 — Supernus Expands Partnership With MERGE as AI-Powered (globenewswire.com)
2026-04-07 — SUPERNUS PHARMACEUTICALS, INC. Reports Material Event | SUPN Form 8-K (stocktitan.net)
2026-04-07 — Supernus Pharmaceuticals Inc enters asset purchase agreement with Navitor on April 1, 2026 | MarketScreener (marketscreener.com)
Company details
Supernus serves the medical and pharmaceutical manufacturing sectors with a commercial portfolio spanning neurology and psychiatry indications. Supernus Pharmaceuticals, Inc. was founded in 2005, has an estimated 500-1,000 employees, and is headquartered in Rockville, Maryland.
Frequently asked questions
What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals is a biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, with 500-1,000 employees and estimated revenue of $500M-1B. It develops and commercializes treatments for central nervous system disorders including opioid use disorder, ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine. In November 2026, Supernus completed a merger with Indivior to create a diversified CNS biopharmaceutical company.
Where is Supernus Pharmaceuticals, Inc. headquartered?
Supernus Pharmaceuticals, Inc. is headquartered in Rockville, Maryland (9715 Key West Avenue, Rockville, Maryland, 20850).
When was Supernus Pharmaceuticals, Inc. founded?
Supernus Pharmaceuticals, Inc. was founded in 2005.
How big is Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals, Inc. has an estimated 500-1,000 employees, with revenue in the $500M-1B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
